Consistent with the goals ofthe Rare Diseases Clinical Research Network (RDCRN), the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Clinical Research Projects for Observational/Longitudinal Studies or Clinical Trials have been developed in joint partnership with patient advocacy groups (PAGs) with the objective of answering immediately important questions concerning the rare diseases eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC).
We aim to 1) better define the diagnostic and clinical features of these diseases (Project 1);2) determine whether the level of tissue eosinophils, a parameter that is currently required for disease diagnosis, is an adequate measurement of clinical outcome as it has so far been assumed that the level reflects disease severity and adverse prognosis (Project 1);3) develop validated clinical outcome metrics (COMs) that can be used to quantitatively monitor disease (Project 1);4) identify and refine biomarkers on the basis of novel approaches that take advantage of direct procurement of readily accessible diseased tissue that will be subjected to whole-genome transcriptome profiling (Project 1 and Project 2);5) conduct a clinical trial that optimizes therapy for the most common of these diseases (EoE) on the basis of currently available approaches - dietary elimination diets and glucocorticoids (Project 2);and 6) develop a personalized and predictive medicine approach to understanding and treating these diseases (Project 1 and Project 2).
The proposed clinical research projects have been developed in partnership with patient advocacy groups with the objective of answering immediately important questions concerning the understanding and treatment ofthe rare diseases eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis. These diseases are painful, lifelong diseases that make it difficult or impossible for individuals to eat many or all foods.
Philpott, Hamish; Dellon, Evan S (2018) The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? J Gastroenterol 53:165-171 |
Hill, David A; Grundmeier, Robert W; Ramos, Mark et al. (2018) Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. J Allergy Clin Immunol Pract 6:1528-1533 |
Safroneeva, Ekaterina; Straumann, Alex; Schoepfer, Alain M (2018) Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis. Gastrointest Endosc Clin N Am 28:35-45 |
Muir, Amanda; Moore, Hillary; Spergel, Jonathan (2018) To treat or not to treat: The minimally symptomatic EoE patient. Ann Allergy Asthma Immunol : |
Naramore, Sara; Gupta, Sandeep K (2018) Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions. J Pediatr Gastroenterol Nutr 67:318-321 |
Steinbach, Erin C; Hernandez, Michelle; Dellon, Evan S (2018) Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 6:1483-1495 |
Spergel, Jonathan; Aceves, Seema S (2018) Allergic components of eosinophilic esophagitis. J Allergy Clin Immunol 142:1-8 |
Hill, David A; Spergel, Jonathan M (2018) Is eosinophilic esophagitis a member of the atopic march? Ann Allergy Asthma Immunol 120:113-114 |
Spergel, Jonathan M; Dellon, Evan S; Liacouras, Chris A et al. (2018) Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference. Ann Allergy Asthma Immunol 121:281-284 |
Wechsler, Joshua B; Hirano, Ikuo (2018) Biological therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol 142:24-31.e2 |
Showing the most recent 10 out of 103 publications